Tetratherix (ASX:TTX) said the second stage of the TUTELA trial, a first in-human clinical investigation of the Tutelix hydrogel spacer, was initiated and patient recruitment is underway, according to a Monday Australian bourse filing.
Its Tegenix bone regeneration animal study implantation began, and the US Food and Drug Administration submission timing remains on track, it added.
Its TegenEOS animal study implementation is planned for the second quarter of fiscal year 2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.